This study examines the hypothesis, that subcutaneous administration of liraglutide, an analogue of the incretin glucagon-like peptide 1, over 5 weeks improves memory functions in healthy humans.

Inclusion Criteria:

• Male sex
• Age 18-35 years
• Body mass index between 19 and 25 kg/m2
• Non-smoker

Exclusion Criteria:

• Receipt of any drug within 4 weeks prior to this trial
• Any known acute or chronic disease of the brain, heart, lung, kidney,liver, pancreas or gastrointestinal tract, any metabolic, endocrine or psychiatric disease.
• Brady- and Tachycardia, i.e. heart rate < 50 and > 90 beats per minute.
• Hypertension (systolic blood pressure > 150 mmHg, diastolic blood pressure > 90 mmHg).
• Hyperlipidemia (cholesterol, LDL, triglyceride > two times the upper reference limit based on analysis from the central laboratory)
• Impaired hepatic function measured as alanine aminotransferase (ALAT) > two times the upper reference limit based on analysis from the central laboratory
• Impaired renal function measured as creatinine > 120 µmol/l based on analysis from the central laboratory
• Family history of diabetes
• History of any eating disorder
• Known or suspected allergy to trial products
• History of drug or alcohol abuse within the last five years prior to screening